These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 38300281)

  • 1. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
    Yu Z; Xu F; Zou J
    Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L; Fan J; Qian R; Luo P; Zhang J
    Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
    Blakely CM; Urisman A; Gubens MA; Mulvey CK; Allen GM; Shiboski SC; Rotow JK; Chakrabarti T; Kerr DL; Aredo JV; Bacaltos B; Gee M; Tan L; Jones KD; Devine WP; Doebele RC; Aisner DL; Patil T; Schenk EL; Bivona TG; Riess JW; Coleman M; Kratz JR; Jablons DM
    J Clin Oncol; 2024 Sep; 42(26):3105-3114. PubMed ID: 39028931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.
    Li L; Huang Q; Sun J; Yan F; Wei W; Li Z; Liu L; Deng J
    Acta Oncol; 2022 Nov; 61(11):1347-1353. PubMed ID: 36240432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials.
    Sun L; Guo YJ; Song J; Wang YR; Zhang SL; Huang LT; Zhao JZ; Jing W; Han CB; Ma JT
    Front Oncol; 2020; 10():586596. PubMed ID: 33511076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
    Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
    J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis.
    Cui S; Zhang Y; Liu L; Li Y; Zhou R; Huang X; Cao S; Huo X; Wang N
    Ann Palliat Med; 2021 Feb; 10(2):1851-1860. PubMed ID: 33474947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
    Yang F; Zhang W; Shang X; Liu N; Ma X; Qin J; Zhang Y; Liu Y; Wang X
    Crit Rev Oncol Hematol; 2022 Sep; 177():103760. PubMed ID: 35870763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer.
    Byun JY; Han S; Qdaisat A; Park C
    Expert Opin Drug Saf; 2024 Aug; 23(8):1007-1015. PubMed ID: 38088244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
    Xu Y; Ji H; Zhang Y; Xiong L; Han B; Zhong H; Xu J; Zhong R
    Oncologist; 2024 Jul; 29(7):e932-e940. PubMed ID: 38529688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
    Araki T; Kanda S; Obara M; Agatsuma T; Kakizaki Y; Hama M; Yamamoto H; Takada M; Yamamoto M; Matsuo A; Kondo D; Komatsu M; Sonehara K; Tateishi K; Hanaoka M; Koizumi T
    Respir Investig; 2024 Mar; 62(2):262-268. PubMed ID: 38245931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.
    Huang L; Huang H; Zhou XP; Liu JF; Li CR; Fang M; Wu JR
    Medicine (Baltimore); 2019 Oct; 98(43):e17705. PubMed ID: 31651902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
    Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
    Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
    [No Abstract]   [Full Text] [Related]  

  • 18. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.
    Lv C; Fang W; Wu N; Jiao W; Xu S; Ma H; Wang J; Wang R; Ji C; Li S; Wang Y; Yan S; Lu F; Pei Y; Liu Y; Yang Y
    Lung Cancer; 2023 Apr; 178():151-156. PubMed ID: 36863124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncommon
    Okuma Y; Shimokawa M; Hashimoto K; Mizutani H; Wakui H; Murakami S; Atagi S; Minato K; Seike M; Ohe Y; Kubota K;
    Future Oncol; 2022 Feb; 18(5):523-531. PubMed ID: 35034503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
    Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
    Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.